Health IT company Apervita will leverage Diameter Health’s capabilities — which include cleaning and enriching clinical data — to enhance data quality for stakeholders looking to create value-based care contracts.
Rebuild clinical trials in the image of patient need. Join Sanofi, Janssen, FDA, Pfizer and more [Sponsored]
Clinical 2021 is US and EU pharma’s leading event for clinical innovators – join 500+ executive attendees from across the globe to meet and learn virtually.
CIOs need to look beyond just EHRs and explore standalone platforms to enhance care delivery – keeping focused on reliable patient data and streamlined clinical workflows.
Shots: The company reported that the COVID-19 vaccine is safe, well-tolerated & immunogenic in the P-I/II study & plans to initiate P-III clinical trial in ~30000 volunteers upon receiving necessary approvals The P-II study of ZyCoV-D had been conducted in ~1000 healthy adult volunteers as… Read More »Zydus Cadila Seeks Approval to Commence P-III Clinical Study of ZyCoV-D
Shots: The P-I clinical trial involves assessing CT-P59 (20/40/80 mg/kg) vs PBO in 18 patients with mild symptoms of SARS-COV-2 infection who were randomized into 3 cohorts Results: patients demonstrated a 44% reduction in mean clinical recovery time, while no patients required hospitalization or antiviral… Read More »Celltrion Reports Results of CT-P59 in P-I Study for COVID-19
Innovent and Lilly Report Results of Tyvyt (sintilimab) in Seven Clinical Studies to be Presented at the ESMO ASIA Congress 2020
Shots: The 7 studies include one Proffered Paper Oral Presentation & 6 e-posters, covering indications including lung cancer, liver cancer, gastric cancer, & esophageal cancer The 1st study involves assessing of sintilimab + bevacizumab biosimilar vs sorafenib as 1L treatment for aHCC while the 2nd… Read More »Innovent and Lilly Report Results of Tyvyt (sintilimab) in Seven Clinical Studies to be Presented at the ESMO ASIA Congress 2020
Boehringer Ingelheim Initiates P-II Study of BI 764198 for Patients with Severe Respiratory Illness from COVID-19
Shots: The P-II trial will assess BI 764198 (qd for ~4wks.) in patients hospitalized for COVID-19 with expected enrollment initiation in Oct’2020. The 1EPs will be the percentage of patients who are alive and free of mechanical ventilation at day 29 of treatment while other… Read More »Boehringer Ingelheim Initiates P-II Study of BI 764198 for Patients with Severe Respiratory Illness from COVID-19
Shots: The company has expanded its Direct-to-Patient service offerings for supporting decentralized clinical trials to lessen clinical trial lengths and costs while increasing patient enrollment and participation rates The company’s expanded Direct-to-Patient services build on its global Clinical Site-to-Patient program that launched in early 2020… Read More »Thermo Fisher Expands its Direct-to-Patient Service Offerings
Shots: GSK reported that its RSV vaccines for maternal immunization (GSK3888550A) and older adults (GSK3844766A) were well-tolerated and highly immunogenic in P-I/II clinical studies. Both the candidate vaccines contain a recombinant RSVPreF3, that triggers the required immune response The GSK3844766A was first tested in 48… Read More »GSK Presents Results of Maternal & Older Adults RSV Vaccines at IDWeek 2020
Roche and Prothena to Advance Prasinezumab in P-IIb Study for Patients with Early Parkinson’s Disease
Shots: The companies will advance the prasinezumab into a P-IIb study in patients with early Parkinson’s disease based on positive signals of efficacy consistent with disease modification in the PASADENA study The study is designed to further assess the efficacy of prasinezumab by expanding upon… Read More »Roche and Prothena to Advance Prasinezumab in P-IIb Study for Patients with Early Parkinson’s Disease
Shots: The independent DSMB recommended pausing the enrollment of the ACTIV-3 clinical trial. The trial is evaluating Lilly’s bamlanivimab (LY-CoV555, 7000mg) + remdesivir as a treatment for COVID-19 in hospitalized patients, and is sponsored by the NIAID Lilly trusts the judgment & supports independent DSMB… Read More »Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to Safety Concerns
PRISYM ID appoints Software Delivery Manager to oversee team developing new clinical labeling solutions Wokingham, United Kingdom — 30 September 2020 — PRISYM ID, a leading provider of regulated content and label management solutions, has announced the appointment of Amresh Bangalore as Software Delivery Manager. In his new role, Amresh will be responsible for overseeing and coordinating the people, resources and processes… Read More »PRISYM ID appoints Software Delivery Manager to oversee clinical labeling team
The clinical manifestations of COVID-19 are varied, and patients are known to have rapidly changing signs and symptoms that must be tracked with laboratory testing. A patient may start his treatment journey with his primary care physician and will include lab centers, diagnostic centers, inpatient,… Read More »Terminology standards bridging gaps between health systems during COVID-19
CMS requirements for approved clinical decision support mechanisms could cause extra burden and more keystrokes for physicians attempting to meet appropriate use criteria.